PYC Therapeutics Nears New Drug Milestone for RP11
Company Announcements

PYC Therapeutics Nears New Drug Milestone for RP11

PYC Therapeutics Limited (AU:PYC) has released an update.

PYC Therapeutics has achieved a milestone by completing the dosing of the fourth patient cohort in their Single Ascending Dose study for a pioneering drug targeting Retinitis Pigmentosa type 11 (RP11), a genetic blinding disease in children. The company is poised to initiate a Multiple Ascending Dose study, with the end goal of submitting a New Drug Application by 2027 for this potential treatment, addressing a market with over $1 billion annual potential.

For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!